全文获取类型
收费全文 | 638篇 |
免费 | 45篇 |
国内免费 | 3篇 |
学科分类
医药卫生 | 686篇 |
出版年
2024年 | 1篇 |
2023年 | 11篇 |
2022年 | 10篇 |
2021年 | 11篇 |
2020年 | 18篇 |
2019年 | 16篇 |
2018年 | 20篇 |
2017年 | 7篇 |
2016年 | 18篇 |
2015年 | 20篇 |
2014年 | 21篇 |
2013年 | 35篇 |
2012年 | 47篇 |
2011年 | 55篇 |
2010年 | 25篇 |
2009年 | 24篇 |
2008年 | 35篇 |
2007年 | 36篇 |
2006年 | 40篇 |
2005年 | 46篇 |
2004年 | 46篇 |
2003年 | 35篇 |
2002年 | 34篇 |
2001年 | 4篇 |
2000年 | 6篇 |
1999年 | 4篇 |
1998年 | 5篇 |
1997年 | 5篇 |
1996年 | 5篇 |
1995年 | 6篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 5篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1974年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有686条查询结果,搜索用时 0 毫秒
671.
672.
Cusumano G Margaritora S Porziella V Meacci E Piraino A Vita ML Tessitore A Congedo MT Filotico M Cafarotti S Granone P 《Annali italiani di chirurgia》2007,78(5):389-391
Malignant pleural effusion is a frequent condition with important prognostic repercussions on duration and quality of life. The neoplasms that more frequently determine pleural effusion are lung and breast cancer and pleural mesothelioma. Lymphomas, tumours of the genitourinary tract and gastrointestinal tract as a group account for a further 25%. Surgical treatment has palliative purposes and finalized to reduction symptoms and to improve quality of life. More frequent clinical presentation is a massive pleural efusion associated to dyspnoea and cough. Pleural aspiration is the first choice treatment but the recurrence rate equals to 100% within 1 month. Repeated pleural aspirations are indicated in those patients that have lower expectation of life. The recurrence risk can be reduced with chemical pleurodesis that allows the adhesion between pleural surfaces. Pleurodesis can be realized by the instillation of several substances by the tube of drainage (slurry) or during thoracoscopy (poudrage). Video Assisted Thoracoscopy (VATS) is a safe and well tolerated technique, a complication rate is lower than 0.5%, VATS can be used to obtain diagnosis and to treat patients with malignant pleural effusion and better expectation of life. 相似文献
673.
Trucco Aguirre E Olano Gossweiler C Méndez Pereira C Isasi Capelo ME Isasi Capelo ES Rondan Olivera M 《Gastroenterologia y hepatologia》2007,30(9):538-540
Systemic scleroderma (SS) affects the connective tissue, with involvement of multiple organs. Digestive system involvement occurs in 50% of patients. SS is frequently associated with other autoimmune diseases. Celiac disease (CD) is an autoimmune disorder that affects the digestive system and is trigged by gluten intake. These two diseases share some HLA antigens. We describe the case of a woman with a diagnosis of SS who presented with weight loss. CD was diagnosed. Because the literature on this topic is scarce, this case is compared with a prior review and some similarities were found. Diagnosis of CD in patients with SS may be difficult but is essential to achieve optimal treatment response in patients with poor quality of life. 相似文献
674.
675.
Piero Farruggia Antonino Trizzino Silvio Maringhini Antonella Grigoli Chiara Sapia Mariella D’Alessandro Serena Tropia Paolo D’Angelo 《Indian journal of pediatrics》2010,77(10):1147-1149
An association between nephrotic syndrome and extrarenal neoplasia was described for the first time in 1922. Since then a
large number of cases have been published, few of them describing the link between Hodgkin disease (HD) and nephrotic syndrome
(NS). It shows that the incidence of nephrotic syndrome in Hodgkin lymphoma is less than 1%. Till date, to the best of author’s
knowledge, there are about 50 pediatric cases published, no one among Italian children. In the present paper, the authors
report 2 cases observed in their department in the 7 yrs period. 相似文献
676.
677.
678.
Todaro M Zerilli M Triolo G Iovino F Patti M Accardo-Palumbo A di Gaudio F Turco MC Petrella A de Maria R Stassi G 《Arthritis and rheumatism》2005,52(7):2179-2191
OBJECTIVE: To determine whether prolongation of the inflammatory reaction in patients with Beh?et's disease (BD) is related to apoptosis resistance and is associated with the up-regulation of antiapoptotic factors. METHODS: The percentage of cell death was evaluated by flow cytometry in peripheral blood mononuclear cells from 35 patients with BD and 30 healthy volunteers. The expression levels of antiapoptotic factors and NF-kappaB regulatory proteins were measured using Western blotting and immunohistochemical analyses. To down-regulate NF-kappaB nuclear translocation, BD T lymphocytes were exposed in vitro to thalidomide and subjected to transfection with NF-kappaB small interfering RNA. RESULTS: Although CD95 is highly expressed in BD T cells, the absence of sensitivity to CD95-induced apoptosis observed may be attributable to the inhibitory action of antiapoptotic genes. Immunoblot analysis for major antiapoptotic proteins showed considerable up-regulation of the short form of cellular FLIP (cFLIP) and Bcl-x(L) in BD activated T cells, while levels of Bcl-2, caspase 3, and caspase 8 in activated T cells from patients with BD were comparable with those in activated T cells from normal donors. Moreover, expression of IKK and IkappaB was up-regulated, whereas NF-kappaB translocated to the nucleus in BD T cells, suggesting that NF-kappaB activation may modulate the expression of antiapoptotic genes. Interestingly, thalidomide and NF-kappaB small interfering RNA down-regulated cFLIP and Bcl-x(L) expression levels and sensitized BD activated T cells to CD95-induced apoptosis. CONCLUSION: Taken together, these results indicate that NF-kappaB contributes to the regulation of the apoptosis-related factors and death receptors leading to apoptosis resistance in BD T cell subsets. Our results suggest that NF-kappaB plays a crucial role in the pathogenesis of BD, and that its pharmacologic control could represent a key strategy in modulating specific immune-mediated disease. 相似文献
679.
Laurent Garderet Simona Iacobelli Linda Koster Hartmut Goldschmidt Jan-Erik Johansson Jean Henri Bourhis Marta Krejci Xavier Leleu Michael Potter Didier Blaise Christian Koenecke Christian Peschel Jakub Radocha Bernd Metzner Pascal Lenain Kerstin Schäfer-Eckart David Pohlreich Mariella Grasso Nicolaus Kröger 《Biology of blood and marrow transplantation》2018,24(7):1372-1378
To evaluate the outcomes of salvage third autologous stem cell transplantation (ASCT) in patients with relapsed multiple myeloma. We analyzed 570 patients who had undergone a third ASCT between 1997 and 2010 (European Society for Blood and Marrow Transplantation data), of whom 482 patients underwent tandem ASCT and a third ASCT at first relapse (AARA group) and 88 patients underwent an upfront ASCT with second and third transplantations after subsequent relapses (ARARA group). With a median follow-up after salvage third ASCT of 61 months in the AARA group and 48 months in the ARARA group, the day +100 nonrelapse mortality in the 2 groups was 4% and 7%, the incidence of second primary malignancy was 6% and 7%, the median progression-free survival was 13 and 8 months, and median overall survival (OS) was 33 and 15 months. In the AARA group, according to the relapse-free interval (RFI) from the second ASCT, the median OS after the third ASCT was 17 months if the RFI was <18 months, 37 months if the RFI was between 18 and 36 months, and 64 months if the RFI was ≥36 months (P?<?.001). In the ARARA group, the median OS after the third ASCT was 7 months if the RFI was <6 months, 13 months if the RFI was between 6 and 18 months, and 27 months if the RFI was ≥18 months (P?<?.001). In a multivariate analysis of the AARA group, the favorable prognostic factor was an RFI after second ASCT of ≥18 months. Progressive disease and a Karnofsky Performance Status score of <70 at third ASCT were unfavorable factors. A salvage third ASCT is of value for patients with relapsed myeloma, particularly for those with a long duration of response and chemosensitive disease at the time of transplantation. 相似文献
680.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial 总被引:7,自引:2,他引:7 下载免费PDF全文
Palumbo A Bringhen S Petrucci MT Musto P Rossini F Nunzi M Lauta VM Bergonzi C Barbui A Caravita T Capaldi A Pregno P Guglielmelli T Grasso M Callea V Bertola A Cavallo F Falco P Rus C Massaia M Mandelli F Carella AM Pogliani E Liberati AM Dammacco F Ciccone G Boccadoro M 《Blood》2004,104(10):3052-3057
High-dose therapy is an effective standard treatment for multiple myeloma patients. Evidence that intermediate-dose therapy improves survival is limited. At diagnosis, about 70% of patients are older than 65. Intermediate-dose regimen is very well tolerated in older patients. In a multicenter study, 194 patients were randomized to receive at diagnosis either conventional chemotherapy (6 courses of oral melphalan and prednisone [MP]) or intermediate-dose therapy (2 courses of melphalan at 100 mg/m(2) [MEL100]) with stem cell support. Response rate was higher after MEL100. Near-complete remission (nCR) was 6% after MP and 25% after MEL100 (P = .0002). At 3 years, MEL100 increased event-free survival (EFS) from 16% to 37% and overall survival (OS) from 62% to 77% (P < .001). Similar results were observed in patients aged 65 to 70: nCR was 8% after MP and 25% after MEL100 (P = .05); at 3 years, MEL100 improved EFS from 18% to 31% (P = .01) and OS from 58% to 73% (P = .01). Patients aged 65 to 70 had a median OS of 37.2 months (MP) versus 58 months (MEL100). Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients. 相似文献